Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in DDR2-mutated tumors (MATCH-Subprotocol X)
NCT04439305Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Feb 2016
- Primary completion
- Jun 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in malignant solid neoplasm, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Planned start Feb 2016; status: withdrawn.
02
Drugs
dasatinib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439305.